---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-014246"
form_type: "8-K"
ticker: "MYO"
cik: "0001369290"
company_name: "MYOMO, INC."
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T04:59:17.873288+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Myomo Q2 revenue up 18% to $3.7M; record pipeline adds 52% YoY; net loss widens to $0.42/share

## Summary
- Revenue $3.7M (+18% YoY, +28% seq); product units 80, flat YoY; ASP up via direct billing (83% of revenue).
- Record 420 new patient pipeline adds (+52% YoY); total pipeline 1,049; cost per addition halved from Q4 2021 to ~$2,470.
- Gross margin 65.5%, down 550 bps YoY; net loss $2.9M ($0.42/shr) vs $2.6M ($0.46/shr) in Q2 2021.
- Backlog 163 units (+2% YoY); operating loss $2.9M vs $2.6M; cash $10.2M; entered ELOC with Keystone Capital.
- License payment from China JV delayed; expects sequential Q3 growth but lower YoY revenue; pipeline supports 12-mo outlook.

## SEC filing metadata
- accession: 0000950170-22-014246
- form_type: 8-K
- ticker: MYO
- cik: 0001369290
- company_name: MYOMO, INC.
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369290/000095017022014246/0000950170-22-014246-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369290/000095017022014246/myo-20220803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-014246
- JSON: https://secwatch.observer/filing/0000950170-22-014246.json
- Plain text: https://secwatch.observer/filing/0000950170-22-014246.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.